BD uplifts FY26 revenue outlook based on steady portfolio performance

In a reversal from its previously reported quarter, Becton Dickinson and Company (BD) has lifted its fiscal year 2026 (FY26) profit outlook during the release of its Q2 2026 financials.

Reporting revenues of around $4.7bn in Q2 of FY26, indicative of a 5.2% uptick year-over-year (YoY), BD now anticipates its FY26 earnings per share to fall in the $12.52 to $12.72 per share range, up from the $12.35 to $12.65 range outlined previously.

BD elected to trim its FY26 outlook upon the release of its Q1 FY26 earnings in February 2026. At the time, BD said the decision had been made to account for the company’s divestment of its biosciences & diagnostic solutions business to Waters, which completed on 9 February 2026.

BD released its financials ahead of market open. The revised FY26 outlook seems to have satisfied investors, as BD’s stock was up by 0.26% to $145 per share as at 7:20am ET on 7 May, up from $144.76 previously.

Reflecting on the company’s Q2 performance and explaining the rationale for its revenue outlook’s uplift, BD CEO Tom Polen said: “Based on our first‑half performance and improved visibility into the balance of the year, we are raising our full‑year adjusted EPS guidance and reaffirming our revenue growth expectations. We remain focused on disciplined execution of our New BD strategy, including advancing our commercial and innovation initiatives across key growth platforms, expanding margins, and delivering on our capital allocation framework, all to drive sustainable long‑term shareholder value.”

In Q2, each of BD’s business segments witnessed YoY growth. Medical essentials represented the biggest revenue-generating segment at around $1.65bn, corresponding to a 4.7% uptick YoY. This was followed by interventional and connected care as the second and third biggest areas for BD, achieving revenue of around $1.36bn and $1.1bn, equating to YoY growth of 7.3% and 4.9%, respectively.

Other medtech companies that have recently released their latest financials include continuous glucose monitoring (CGM) specialist Dexcom and Stryker. Both companies maintained their 2026 outlook, with Stryker doing so in spite of a challenging Q1 that was constrained by a cyberattack that disrupted its global operations. GE HealthCare, meanwhile, chose to trim its 2026 outlook on the basis of rising freight costs.

“BD uplifts FY26 revenue outlook based on steady portfolio performance” was originally created and published by Medical Device Network, a GlobalData owned brand.

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.